FC
ABBV icon

Fairscale Capital’s AbbVie ABBV Stock Holding History

Fairscale Capital’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$182K Hold
839
– – 0.13% 103
2025
Q4 		$192K Buy
839
+218
+35% +$49.7K 0.13% 99
2025
Q3 		$144K Hold
621
– – 0.1% 108
2025
Q2 		$117K Buy
621
+147
+31% +$27.3K 0.09% 127
2025
Q1 		$99.3K Sell
474
-34
-7% -$6.61K 0.09% 124
2024
Q4 		$90.2K Hold
508
– – 0.08% 126
2024
Q3 		$100K Hold
508
– – 0.09% 124
2024
Q2 		$85.9K Buy
+508
New +$84.2K 0.08% 127

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fairscale Capital's ABBV Position: Q1 2026 in Review

Fairscale Capital held its AbbVie (ABBV) position steady in Q1 2026 at 839 shares worth $182K. The position accounts for 0.13% of the portfolio, ranked #103.

Fairscale Capital first reported a position in ABBV in Q2 2024 and has held it in 8 quarters since. The position peaked at $192K in Q4 2025. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Fairscale Capital held 839 shares of AbbVie worth $182K as of Q1 2026.
  • Fairscale Capital left its AbbVie share count unchanged in Q1 2026.
  • AbbVie made up 0.13% of Fairscale Capital's portfolio in Q1 2026, its #103 holding.
  • Fairscale Capital first reported a position in AbbVie in Q2 2024 and has held it in 8 quarters since.
  • Fairscale Capital's AbbVie position peaked at $192K in Q4 2025.
  • 4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Fairscale Capital's 13F filing for Q1 2026, filed 11 May 2026.